Eon Ting

Eon Ting is the Director of Payer Evidence, Methods, & Access Affairs at AstraZeneca Canada, where he partners with clinical experts, academics, and industry leaders to advance methods and bring out the best in health economics and HTA. With nearly two decades of experience spanning market access, HEOR, and new product launches, Eon is excited to work together on a sustainable, innovation-ready, patient-centered healthcare systems.  

Most recently, his focus is on patient preferences in decision-making, artificial intelligence/machine learning (AI/ML) in HTA, and new surrogate endpoint valuation methods. Eon is currently President-Elect at the Canadian Association for Population Therapeutics (CAPT), a scientific advisor at Health Technology Assessment International (HTAi), and an expert reviewer for ISPOR.